Alnylam Releases Findings from TTR Amyloidosis Study | GenomeWeb

Alnylam Pharmaceuticals this week released data from a natural history study designed to measure blood levels of the wild-type and mutant versions of the gene transthyretin in both transthyretin-mediated amyloidosis patients and mutation carriers.

Alnylam is currently conducting a phase I study of an RNAi-based treatment for TTR amyloidosis, a hereditary, systemic disease caused by a mutation in the transthyretin gene (GSN 7/8/2010).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.